监督的迪苏尔菲拉姆应该被视为酒精使用障碍的第一线治疗
1From the Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (SRH).
Journal of addiction medicine
|August 16, 2024
概括
监督的迪苏尔菲拉姆,一种治疗酒精使用障碍 (AUD) 的药物,当被视为行为干预时,显示出有利的疗效. 建议将其重新归类为一线治疗,以改善AUD护理.
科学领域:
- 成 药物 药物 药物 药物
- 药理学 药理学是指药理学的学科.
- 临床试验设计 临床试验设计
背景情况:
- 酒精使用障碍 (AUD) 有限的FDA批准的药物选择.
- 迪苏尔菲拉姆是二线AUD治疗,原因是看起来不一致的证据和安全问题.
- 目前的指导方针往往误解证据,仅依赖双盲随机对照试验 (RCT).
研究的目的:
- 重新评估迪苏尔菲拉姆对酒精使用障碍 (AUD) 的疗效.
- 倡导重新指定监督的迪苏尔菲拉姆作为一线治疗.
- 为了强调考虑dissulfiram的行为干预方面的重要性.
主要方法:
- 对现有证据的审查,包括开放式随机对照试验 (RCT).
- 当被视为药物和行为干预时,对dissulfiram的疗效的分析.
- 对传统双盲RCT证据解释的批评.
主要成果:
- 开放式RCT显示了disulfiram的绝对有利的疗效,特别是在监督的情况下.
- 监督的迪苏尔菲拉姆显示出作为有效的AUD治疗的巨大潜力.
- 传统的证据解释可能低估了迪苏尔菲拉姆的治疗价值.
结论:
- 监督的迪苏尔菲拉姆应该被认为是对酒精使用障碍的第一线干预.
- 应更新治疗指南和临床途径,以反映迪苏尔菲拉姆的疗效.
- 药物成医学界应该重新开始使用迪苏尔菲拉姆作为一种重要的治疗选择.
更多相关视频
08:05A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
Published on: January 5, 2018
9.7K
07:31Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
7.9K
相关概念视频
CNS Depressants: Alcohol and Nicotine
185
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
185
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Substance Use Disorders Affecting Sleep
163
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
163
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
